ChenGuang Biotech Group Co., Ltd. (SHE:300138)

ChenGuang Biotech Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Jan 1, 2021
Cash & Equivalents	2,141	1,802	1,422	1,147	732.59	309.78
Short-Term Investments	-	14.01	17.02	13.75	5.07	2.11
Trading Asset Securities	0.54	8.13	79.85	17.58	0.56	-
Cash & Short-Term Investments	2,141	1,825	1,519	1,178	738.22	311.88
Cash Growth	-16.10%	20.09%	28.98%	59.57%	136.70%	-43.48%
Accounts Receivable	474.9	458.39	474.39	311.4	398.77	306.3
Other Receivables	29.36	9.54	17.17	77.56	12.63	6.76
Receivables	504.26	467.93	491.56	388.96	411.4	313.06
Inventory	1,874	3,862	3,198	2,033	2,229	1,793
Prepaid Expenses	-	-	-	1.48	0.01	0.02
Other Current Assets	1,259	654.03	1,157	1,325	598.8	494.61
Total Current Assets	5,779	6,809	6,367	4,927	3,977	2,912
Property, Plant & Equipment	1,635	1,663	1,696	1,538	1,484	1,244
Long-Term Investments	120.68	112.71	101.47	92.25	173.01	163.27
Goodwill	0.59	0.59	0.59	0.59	0.59	0.59
Other Intangible Assets	333.29	337.01	304.19	308.9	265.71	254.61
Long-Term Deferred Tax Assets	42.17	56.56	44.39	35.79	31.54	23.07
Long-Term Deferred Charges	10.32	8.88	12.63	6.75	3.93	4.12
Other Long-Term Assets	39.8	35.21	13.89	14.32	19.83	53.06
Total Assets	7,960	9,023	8,540	6,924	5,955	4,654
Accounts Payable	49.18	153.85	79.53	55.96	36.09	27.64
Accrued Expenses	96.55	117.52	122.58	146.93	105.49	83.54
Short-Term Debt	1,966	2,304	2,599	2,043	1,839	1,038
Current Portion of Long-Term Debt	1,674	1,537	750.56	0.62	300.52	6.41
Current Portion of Leases	-	0.23	0.22	0.21	0.06	-
Current Income Taxes Payable	25.66	18.82	41.16	41.82	18.22	8.51
Current Unearned Revenue	181.04	335.29	236.04	365.61	307.91	194.23
Other Current Liabilities	172.58	129.88	123.01	102.82	75.03	67.91
Total Current Liabilities	4,165	4,596	3,952	2,757	2,682	1,426
Long-Term Debt	199	1,068	865	770	303.1	1,031
Long-Term Leases	3.67	3.56	3.79	4	2.67	-
Long-Term Unearned Revenue	154.76	150.44	117.72	93.69	83.6	67.99
Long-Term Deferred Tax Liabilities	13.88	14.7	16.57	16.64	14.56	12.43
Other Long-Term Liabilities	36.98	35.12	52.23	68.08	85.79	57.24
Total Liabilities	4,573	5,868	5,007	3,710	3,172	2,595
Common Stock	483.1	483.1	532.77	532.77	532.77	520.31
Additional Paid-In Capital	581.98	581.98	1,022	1,022	1,025	753.36
Retained Earnings	2,326	2,085	2,056	1,662	1,294	996.25
Treasury Stock	-	-	-95.84	-	-	-232.7
Comprehensive Income & Other	-56.79	-40.87	-44.2	-51.43	-67.2	26.92
Total Common Equity	3,335	3,109	3,470	3,165	2,785	2,064
Minority Interest	52.7	45.2	61.79	49.26	-2.1	-4.61
Shareholders' Equity	3,387	3,155	3,532	3,214	2,783	2,060
Total Liabilities & Equity	7,960	9,023	8,540	6,924	5,955	4,654
Total Debt	3,842	4,912	4,218	2,818	2,445	2,075
Net Cash (Debt)	-1,701	-3,088	-2,699	-1,640	-1,707	-1,764
Net Cash Per Share	-3.49	-5.97	-5.07	-3.08	-3.23	-3.47
Filing Date Shares Outstanding	483.1	483.1	532.77	532.77	532.77	490.01
Total Common Shares Outstanding	483.1	483.1	532.77	532.77	532.77	490.01
Working Capital	1,614	2,213	2,415	2,170	1,295	1,486
Book Value Per Share	6.90	6.44	6.51	5.94	5.23	4.21
Tangible Book Value	3,001	2,772	3,166	2,855	2,519	1,809
Tangible Book Value Per Share	6.21	5.74	5.94	5.36	4.73	3.69
Buildings	-	968.65	865.58	-	709.91	583.91
Machinery	-	1,549	1,359	-	1,139	948.63
Construction In Progress	-	112.43	295.48	-	219.84	204.12

Source: S&P Global Market Intelligence. Standard template. Financial Sources.